VIRIDIAN THERAPEUTICS INC (VRDN) Stock News

USA - NASDAQ:VRDN - US92790C1045 - Common Stock

18.62 USD

-0.04 (-0.21%)

Last: 9/17/2025, 8:11:10 PM

18.62 USD

0 (0%)

After Hours: 9/17/2025, 8:11:10 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VRDN Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

14 days ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Benzinga

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

a month ago - By: The Motley Fool

Viridian (VRDN) Q2 Net Loss Widens 55%

4 months ago - By: Benzinga

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

a month ago - By: Zacks Investment Research - Mentions: FATE

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

a month ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

a month ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

4 months ago - By: Zacks Investment Research - Mentions: IOVA

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates

4 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

5 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

6 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

7 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

9 months ago - By: Investor's Business Daily - Mentions: AMGN

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

9 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

9 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

10 months ago - By: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)